Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 518

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis

Open access
Titulaer, Maarten J., Höftberger, Romana, Iizuka, Takahiro, Leypoldt, Frank, McCracken, Lindsey, Cellucci, Tania, Benson, Leslie A., Shu, Huidy, Irioka, Takashi, Hirano, Makito, Singh, Gagandeep, Cobo Calvo, Alvaro, Kaida, Kenichi, Morales, Pamela S., Wirtz, Paul W., Yamamoto, Tomotaka, Reindl, Markus, Rosenfeld, Myrna R., Graus, Francesc, Saiz, Albert, Dalmau, Josep·2014·Annals of Neurology

Abstract

Objective: To report the clinical, radiological, and immunological association of demyelinating disorders with anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis. Methods: Clinical and radiological analysis was done of a cohort of 691 patients with anti‐NMDAR encephalitis. Determination of antibodies to NMDAR, aquaporin‐4 (AQP4), and myelin oligodendrocyte glycoprotein (MOG) was performed using brain immunohistochemistry and cell‐based assays. Results: Twenty‐three of 691 patients with anti‐NMDAR encephalitis had prominent magnetic resonance imaging (MRI) and/or clinical features of demyelination. Group 1 included 12 patients in whom anti‐NMDAR encephalitis was preceded or followed by independent episodes of neuromyelitis optica (NMO) spectrum disorder (5 cases, 4 anti‐AQP4 positive) or brainstem or multifocal demyelinating syndromes (7 cases, all anti‐MOG positive). Group 2 included 11 patients in whom anti‐NMDAR encephalitis occurred simultaneously with MRI and symptoms compatible with demyelination (5 AQ4 positive, 2 MOG positive). Group 3 (136 controls) included 50 randomly selected patients with typical anti‐NMDAR encephalitis, 56 with NMO, and 30 with multiple sclerosis; NMDAR antibodies were detected only in the 50 anti‐NMDAR patients, MOG antibodies in 3 of 50 anti‐NMDAR and 1 of 56 NMO patients, and AQP4 antibodies in 48 of 56 NMO and 1 of 50 anti‐NMDAR patients (p < 0.0001 for all comparisons with Groups 1 and 2). Most patients improved with immunotherapy, but compared with anti‐NMDAR encephalitis the demyelinating episodes required more intensive therapy and resulted in more residual deficits. Only 1 of 23 NMDAR patients with signs of demyelination had ovarian teratoma compared with 18 of 50 anti‐NMDAR controls (p = 0.011). Interpretation: Patients with anti‐NMDAR encephalitis may develop concurrent or separate episodes of demyelinating disorders, and conversely patients with NMO or demyelinating disorders with atypical symptoms (eg, dyskinesias, psychosis) may have anti‐NMDAR encephalitis. Ann Neurol 2014;75:411–428

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.24117

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 518

Metadata

Authors
Titulaer, M. J., Höftberger, R., Iizuka, T., Leypoldt, F., McCracken, L., Cellucci, T., Benson, L. A., Shu, H., Irioka, T., Hirano, M., Singh, G., Cobo Calvo, A., Kaida, K., Morales, P. S., Wirtz, P. W., Yamamoto, T., Reindl, M., Rosenfeld, M. R., Graus, F., Saiz, A., & Dalmau, J.
Venue
Annals of Neurology
Publisher
Wiley
Published
2014-03
Volume
75
Issue
3
Pages
411-428
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1482033427
Cited by
518
References
31
FWCI
26.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis. https://app.cochat.ai/papers/10.1002/ana.24117
The paper
Titulaer, M. J., Höftberger, R., Iizuka, T., Leypoldt, F., McCracken, L., Cellucci, T., Benson, L. A., Shu, H., Irioka, T., Hirano, M., Singh, G., Cobo Calvo, A., Kaida, K., Morales, P. S., Wirtz, P. W., Yamamoto, T., Reindl, M., Rosenfeld, M. R., Graus, F., . . . Dalmau, J. (2014). Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis. Annals of Neurology. https://doi.org/10.1002/ana.24117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.